Ribosomal Protein L9: Regulator of Protein Synthesis and Cellular Processes

Target Name: RPL9

NCBI ID: G6133

RPL9

Ribosomal Protein L9: Regulator of Protein Synthesis and Cellular Processes

Ribosomal protein L9 (RPL9) is a protein that is expressed in most eukaryotic cells and is involved in various cellular processes. It plays a critical role in the synthesis of protein biosynthesis, which is the process by which cells produce the proteins they need for their normal functioning. RPL9 is a key protein of the Ribosome, a complex protein that is responsible for this process.

The Ribosome is a large organelle that is composed of multiple subunits that are held together by ionic bonds. It is the site of protein synthesis, where mRNA (messenger RNA) is translated into protein. The Ribosome is composed of two major subunits, a small subunit (p) and a large subunit (r), that are held together by a complex of amino acids, called the Ribosome Binders.

RPL9 is one of the Ribosome Binders, which are small proteins that are involved in the stability and initiation of protein synthesis. It is composed of 21 amino acids and has a molecular weight of 30 kDa. RPL9 is primarily localized to the cytoplasm of the cell , where it interacts with various cellular organelles, including the Ribosome, tRNA (transfer RNA), and the factors involved in protein synthesis, such as factors TFII (T-cell factor-inducible) and TFI (T-cell factor-inhibitable).

RPL9 functions as a critical regulator of protein synthesis, particularly in the context of the cell's response to changes in the environment, such as changes in nutrient availability or the introduction of stressors. It is involved in the regulation of various cellular processes, including cell growth , apoptosis (programmed cell death), and autophagy (cellular degradation).

One of the key functions of RPL9 is its role in the regulation of protein synthesis by the Ribosome. RPL9 is involved in the initiation of protein synthesis by interacting with the Ribosome Binders, allowing it to form a complex with the small subunit of the Ribosome. This interaction between RPL9 and the Ribosome is critical for the initiation of protein synthesis and the production of new proteins.

In addition to its role in the Ribosome, RPL9 is also involved in the regulation of protein synthesis by other cellular processes. For example, it is involved in the regulation of cell growth and apoptosis, which are critical processes that are necessary for the survival of the cell. RPL9 has been shown to play a role in the regulation of cell growth by inhibiting the activity of the oncogene p53, which is a key regulator of DNA damage repair.

RPL9 is also involved in the regulation of autophagy, which is the process by which cells break down and recycle their own damaged or unnecessary proteins. Autophagy is an essential process for the survival of the cell and is regulated by various cellular factors, including RPL9.

In conclusion, RPL9 is a key protein that is involved in various cellular processes, including the regulation of protein synthesis by the Ribosome, cell growth, apoptosis, and autophagy. Its function as a critical regulator of these processes makes RPL9 an attractive drug target and a potential biomarker for various diseases. Further research is needed to fully understand the role of RPL9 in cellular processes and its potential as a drug target.

Protein Name: Ribosomal Protein L9

Functions: Component of the large ribosomal subunit (PubMed:23636399, PubMed:32669547). The ribosome is a large ribonucleoprotein complex responsible for the synthesis of proteins in the cell (PubMed:23636399, PubMed:32669547)

The "RPL9 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RPL9 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets